Clinical Efficacy and Safety of Pulsed Dye Laser Combined with Pingyangmycin on Hyperplastic Scar after Acne

Mediators Inflamm. 2022 Aug 28:2022:3305107. doi: 10.1155/2022/3305107. eCollection 2022.

Abstract

Background: Acne is the most common chronic inflammatory disease of hair follicles and sebaceous glands in dermatology. Hyperplastic scar (HS), a very common sequelae of acne, is also the most common scar type in clinical practice.

Objective: This research analyzed the clinical effectiveness and safety of pulsed dye laser (PDL) combined with pingyangmycin (PI) in the treatment of post-acne HS.

Methods: One hundred and nine patients with post-acne HS admitted in June 2020 were selected and divided into a research group (n = 52) and a control group (n = 57) according to the difference in treatment methods. The efficacy, incidence of adverse reactions, skin repair, treatment comfort, and satisfaction were compared between groups.

Results: The total effective rate was higher in the research group compared with the control group. No statistical difference was observed between groups in the incidence of adverse reactions. The research group showed better scar repair, skin improvement, and granulation tissue maturity than the control group. And compared with the control group, the growth factor of the research group was lower, while the treatment comfort and satisfaction, psychological state, and prognosis quality of life were higher. The two groups showed no notable difference in the recurrence rate.

Conclusions: PDL combined with PI can effectively improve the clinical efficacy, scar repair effect, overall skin status, and treatment experience of patients and boost the psychological state and prognostic quality of life of patients, which has great clinical application prospect for the treatment of HS.

MeSH terms

  • Acne Vulgaris*
  • Bleomycin / analogs & derivatives
  • Cicatrix / etiology
  • Cicatrix / pathology
  • Cicatrix / therapy
  • Humans
  • Lasers, Dye* / therapeutic use
  • Quality of Life
  • Treatment Outcome

Substances

  • Bleomycin
  • bleomycetin